Peers of Cytokinetics Inc (CYTK)
Health Care · Biotechnology
Stock price divided by consensus analyst EPS estimates for the next twelve months. A forward-looking valuation multiple.
Latest Forward P/E Ratio
-11.32x
As of Oct 9, 2026
Beyond Forward P/E Ratio, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | Forward P/E Ratio |
|---|---|
| Oct 9, 2026 | -11.32x |
| Oct 8, 2026 | -11.16x |
| Oct 7, 2026 | -11.00x |
| Oct 6, 2026 | -11.04x |
| Oct 5, 2026 | -11.28x |
| Oct 2, 2026 | -11.81x |
| Oct 1, 2026 | -11.81x |
| Sep 30, 2026 | -11.86x |
Forward P/E (NTM) = Current Stock Price ÷ Next Twelve Months (NTM) Consensus EPS Estimate. Chartloom calculates the NTM denominator by summing analyst consensus EPS estimates for the next four fiscal quarters following each trading day (matched by fiscal period-end).
NTM P/E rolls forward each day and uses analyst consensus rather than reported GAAP figures.
Read the general Forward P/E Ratio definition, formula, and analyst usage guide.
Forward P/E Ratio guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
